Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | TACR3 | P29371 | 8/20 | 0.55 |
| ▸ | ACACA | Q13085 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | ACP1 | P24666 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12736407 | 0.92 | KDM4E (0.64) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL16098101 | 0.88 | KDM4E (0.77) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL6913447 | 0.88 | KDM4E (1.00) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL12736408 | 0.87 | KDM4E (0.59) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL12863748 | 0.87 | KDM4E (0.58) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL12736560 | 0.85 | SMN1; SMN2 (0.59) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL8381387 | 0.82 | KDM4E (0.78) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL8349539 | 0.82 | KDM4E (0.78) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL12744586 | 0.81 | KDM4E (0.68) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL374734 | 0.81 | KDM4E (0.72) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893264-B2 | viricides comprising phosphinic acid compounds and/or mixed with carriers, nucleoside analogues, interferons or pegylated interferons; treating hepatitis C or a hepatitis C associated disorders in animals; side effect reduction | GILEAD SCIENCES, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20100240638-A1 | Organic Compounds and their uses | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100240638-A1 | Organic Compounds and their uses | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20090227491-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20080287449-A1 | AZA-TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-11-20 | — | — | US | disclosed |
| US-20080267917-A1 | N-FUNCTIONALIZED AMIDES AS HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080267917-A1 | N-FUNCTIONALIZED AMIDES AS HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080057031-A1 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080057031-A1 | Antiviral phosphinate compounds | PHOSPHO1, MAVS, ITPA | KDM4E 2173/4885SMN1; SMN2 1818/4885ALDH1A1 4695/4885 |
| US-20100240638-A1 | Organic Compounds and their uses | OAT, HAVCR2, CYP3A43 | KDM4E 3330/4885SMN1; SMN2 4331/4885ALDH1A1 302/4885 |
| US-20090227491-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | PHOSPHO1, MAVS, ITPA | KDM4E 2173/4885SMN1; SMN2 1818/4885ALDH1A1 4695/4885 |
| US-20080267917-A1 | N-FUNCTIONALIZED AMIDES AS HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, HPN, SPINT2 | KDM4E 1232/4885SMN1; SMN2 2794/4885ALDH1A1 628/4885 |
| US-20080287449-A1 | AZA-TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS | CTSC, DPP4, ANPEP | KDM4E 425/4885SMN1; SMN2 3278/4885ALDH1A1 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.